Company Analysis
Sign in

Zevra Therapeutics, Inc. (ZVRA)

Nasdaq: ZVRA · Pharmaceutical Preparations · Boston, MA · filing with the SEC since 2008
Full chart Alerts Compare
Grade5.6
◀ Past 4.5● Present 5.8▶ Future 6.1
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

62 patents granted to the 4 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to Zevra Therapeutics, Inc.’s names, not what it holds today.

Patents granted
62
62 utility, 1976 to Dec 31, 2025
Granted in 2025
1
Against 3 in 2024 and 1 in 2023
Applications published
79
4 of them in 2025
Names they are printed under
4
a former name, its own name
By yearGrantedApplications published
'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals13
Organic fine chemistry2
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name4 counted
KEMPHARM, INC. a former name
US, as the owner printed on each patent
57 granted
7 published
KemPharm, Inc. a former name
named as the applicant on its applications, in US
0 granted
61 published
Zevra Therapeutics, Inc. its own name
named as the applicant on its applications, in US
0 granted
11 published
Zevra Therapeutics, Inc. its own name
US, as the owner printed on each patent
5 granted
0 published
Names not counted (2)
Zevra Denmark A/S
Most of its patents print DK; this name counts in US. 0 granted and 8 published under it are not counted.
Zevra Denmark A/S
Most of its patents print DK; this name counts in US. 1 granted and 0 published under it are not counted.
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Mar 18, 202512,251,445Gamma-hydroxybutyrate delivering compounds and processes for making and using themOrganic fine chemistryZevra Therapeutics, Inc.
Sep 17, 202412,091,386D-amphetamine compounds, compositions, and processes for making and using the samePharmaceuticalsZevra Therapeutics, Inc.
Sep 3, 202412,076,316Levorphanol prodrugs and processes for making and using themPharmaceuticalsZevra Therapeutics, Inc.
Jun 18, 202412,012,384Dextrorphan prodrugs and processes for making and using themPharmaceuticalsZevra Therapeutics, Inc.
Sep 12, 202311,753,378Ketamine compounds and processes for making and using themOrganic fine chemistryZevra Therapeutics, Inc.
Nov 22, 202211,505,537Compositions comprising methylphenidate-prodrugs, processes of making and using the samePharmaceuticalsKEMPHARM, INC.
Feb 1, 202211,234,975Levorphanol prodrugs and processes for making and using themPharmaceuticalsKEMPHARM, INC.
Jan 4, 202211,214,544Dextrorphan prodrugs and processes for making and using themPharmaceuticalsKEMPHARM, INC.
Nov 16, 202111,174,229D-amphetamine compounds, compositions, and processes for making and using the samePharmaceuticalsKEMPHARM, INC.
Oct 5, 202111,136,295D-amphetamine compounds, compositions, and processes for making and using the samePharmaceuticalsKEMPHARM, INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 11, 20252025/0375436SERDEXMETHYLPHENIDATE FOR TREATMENT OF IDIOPATHIC HYPERSOMNIAPharmaceuticalsZevra Therapeutics, Inc.
Dec 4, 20252025/0367299GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEMOrganic fine chemistryZevra Therapeutics, Inc.
Jun 12, 20252025/0186591GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEMOrganic fine chemistryZevra Therapeutics, Inc.
Jan 30, 20252025/0032479LEVORPHANOL PRODRUGS AND PROCESSES FOR MAKING AND USING THEMPharmaceuticalsZevra Therapeutics, Inc.
Sep 26, 20242024/0317688DEXTRORPHAN PRODRUGS AND PROCESSES FOR MAKING AND USING THEMPharmaceuticalsZevra Therapeutics, Inc.
Jun 20, 20242024/0199551D-AMPHETAMINE COMPOUNDS, COMPOSITIONS, AND PROCESSES FOR MAKING AND USING THE SAMEPharmaceuticalsZevra Therapeutics, Inc.
Nov 30, 20232023/0382881GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEMOrganic fine chemistryZevra Therapeutics, Inc.
Nov 30, 20232023/0382880GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEMOrganic fine chemistryZevra Therapeutics, Inc. · patent 12,251,445 granted from it
Nov 30, 20232023/0382851GAMMA-HYDROXYBUTYRATE DELIVERING COMPOUNDS AND PROCESSES FOR MAKING AND USING THEMOrganic fine chemistryZevra Therapeutics, Inc.
Nov 9, 20232023/0355550KETAMINE COMPOUNDS AND PROCESSES FOR MAKING AND USING THEMPharmaceuticalsZevra Therapeutics, Inc.
What it applied for, 2024 to 2025: Pharmaceuticals 4 · Organic fine chemistry 2.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton ZVRA · research, not advice